Nasdaq · CIK 0001770069
MPLT MapLight Therapeutics, Inc.
Insider trading from SEC Form 4. Last filing 25 d ago. Close $8.83 on Oct 9, 2026, 0% from the 52-week low and -78% from the high.
MapLight Therapeutics, Inc. (MPLT) has 45 SEC Form 4 filings on file from 10 insiders, the latest filed on Sep 18, 2026. In the last 90 days insiders made 0 open-market buys worth $0 and 1 open-market sell worth $193k, net -$193k.
18 open-market trades have been scored at MPLT. The newest: Kristopher Hanson (General Counsel) sold $193k of stock on Sep 16, 2026, filed Sep 18, 2026, scored 12 (weak), under a 10b5-1 plan. The largest of the 18 shown: Catalyst4, Inc. (10% owner) bought $92M on Oct 28, 2025, scored 56 (moderate). 3 insiders sold within 14 days of each other around May 7, 2026.
MPLT closed at $8.83 on Oct 9, 2026, 0% above its 52-week low and 78% below its 52-week high.
Last 90 days
Price and insider trades, last year
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at MapLight Therapeutics, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 12Weak | Kristopher Hanson General Counsel sell | $193k 16,509 shares | -11% | - | |
| 21Weak | Erin Pennock Foff Chief Medical Officer sell | $127k 4,438 shares | -1% | +128% from low-9% from high | |
| 26Weak | Kristopher Hanson General Counsel sell | $419k 13,917 shares | -8% | +135% from low-6% from high | |
| 40Moderate | Erin Pennock Foff Chief Medical Officer sell | $1.4M 50,280 shares | -13% | +123% from low-11% from high | |
| 26Weak | Kristopher Hanson General Counsel sell | $388k 13,917 shares | -7% | +123% from low-11% from high | |
| 45Moderate | Jonathan Gillis CAAO and PAO sell | $2.1M 69,835 shares | -28% | +139% from low-5% from high | |
| 39Weak | Erin Pennock Foff Chief Medical Officer sell | $87k 3,213 shares | -1% | +110% from low-9% from high | |
| 40Moderate | Jonathan Gillis CAAO and PAO sell | $96k 3,590 shares | -1% | +110% from low-9% from high | |
| 37Weak | Kristopher Hanson General Counsel sell | $49k 1,827 shares | -1% | +110% from low-9% from high | |
| 28Weak | Robert C. Malenka director sell | $260k 14,195 shares | -4% | +40% from low-15% from high | |
| 52Moderate | George Pavlov director buy | $441k 25,000 shares | - | +35% from low-18% from high | |
| 27Weak | Robert C. Malenka director sell | $221k 12,116 shares | -3% | +34% from low-18% from high | |
| 48Moderate | Timothy John Garnett director buy | $253k 14,124 shares | - | +40% from low-15% from high | |
| 25Weak | Robert C. Malenka director sell | $124k 6,863 shares | -2% | +40% from low-15% from high | |
| 26Weak | Robert C. Malenka director sell | $127k 7,040 shares | -2% | +40% from low-15% from high | |
| 35Weak | Robert C. Malenka director sell | $636k 34,398 shares | -9% | +47% from low-11% from high | |
| 56Moderate | Novo Holdings A/S owner buy | $16M 952,941 shares | +35% | 0% from low-9% from high | |
| 56Moderate | Catalyst4, Inc. owner buy | $92M 5,441,176 shares | +38% | 0% from low-9% from high |
Transactions
The newest 50 of 111 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 16, 2026 | Kristopher Hanson General Counsel | SOpen-market sale Voting Common Stock10b5-1 | -16,509 | $11.67 | $193k | 137,044 | 25 d ago |
| Jun 23, 2026 | Timothy John Garnett director | AGrant or award Voting Common Stock | +3,932 | $0.00 | $0 | 53,457 | Jun 25, 2026 |
| Jun 23, 2026 | Martin Babler director | AGrant or award Voting Common Stock | +7,864 | $0.00 | $0 | 7,864 | Jun 25, 2026 |
| Jun 23, 2026 | Troy Cox director | AGrant or award Voting Common Stock | +7,864 | $0.00 | $0 | 7,864 | Jun 25, 2026 |
| Jun 23, 2026 | Troy Cox director | AGrant or award Stock Option (right to buy)derivative | +29,804 | $0.00 | $0 | 29,804 | Jun 25, 2026 |
| Jun 23, 2026 | Martin Babler director | AGrant or award Stock Option (right to buy)derivative | +29,804 | $0.00 | $0 | 29,804 | Jun 25, 2026 |
| Jun 23, 2026 | Timothy John Garnett director | AGrant or award Stock Option (right to buy)derivative | +14,902 | $0.00 | $0 | 14,902 | Jun 25, 2026 |
| May 11, 2026 | Kristopher Hanson General Counsel | SOpen-market sale Voting Common Stock10b5-1 | -284 | $27.61 | $7,841 | 175,964 | May 11, 2026 |
| May 7, 2026 | Erin Pennock Foff Chief Medical Officer | SOpen-market sale Voting Common Stock10b5-1 | -4,321 | $28.52 | $123k | 346,176 | May 11, 2026 |
| May 11, 2026 | Kristopher Hanson General Counsel | SOpen-market sale Voting Common Stock10b5-1 | -846 | $28.70 | $24k | 175,118 | May 11, 2026 |
| May 7, 2026 | Erin Pennock Foff Chief Medical Officer | SOpen-market sale Voting Common Stock10b5-1 | -117 | $29.10 | $3,405 | 346,059 | May 11, 2026 |
| May 11, 2026 | Kristopher Hanson General Counsel | SOpen-market sale Voting Common Stock10b5-1 | -6,979 | $30.04 | $210k | 168,139 | May 11, 2026 |
| May 11, 2026 | Kristopher Hanson General Counsel | SOpen-market sale Voting Common Stock10b5-1 | -5,808 | $30.56 | $177k | 162,331 | May 11, 2026 |
| May 4, 2026 | Erin Pennock Foff Chief Medical Officer | SOpen-market sale Voting Common Stock10b5-1 | -9,180 | $27.50 | $252k | 391,597 | May 6, 2026 |
| May 4, 2026 | Kristopher Hanson General Counsel | SOpen-market sale Voting Common Stock10b5-1 | -9,030 | $27.50 | $248k | 181,135 | May 6, 2026 |
| May 4, 2026 | Erin Pennock Foff Chief Medical Officer | SOpen-market sale Voting Common Stock10b5-1 | -5,460 | $28.37 | $155k | 386,137 | May 6, 2026 |
| May 4, 2026 | Kristopher Hanson General Counsel | SOpen-market sale Voting Common Stock10b5-1 | -3,908 | $28.29 | $111k | 177,227 | May 6, 2026 |
| May 4, 2026 | Erin Pennock Foff Chief Medical Officer | SOpen-market sale Voting Common Stock10b5-1 | -312 | $29.56 | $9,223 | 385,825 | May 6, 2026 |
| May 4, 2026 | Kristopher Hanson General Counsel | SOpen-market sale Voting Common Stock10b5-1 | -296 | $29.56 | $8,750 | 176,931 | May 6, 2026 |
| May 4, 2026 | Erin Pennock Foff Chief Medical Officer | SOpen-market sale Voting Common Stock10b5-1 | -700 | $30.08 | $21k | 385,125 | May 6, 2026 |
| May 4, 2026 | Kristopher Hanson General Counsel | SOpen-market sale Voting Common Stock10b5-1 | -683 | $30.08 | $21k | 176,248 | May 6, 2026 |
| May 5, 2026 | Erin Pennock Foff Chief Medical Officer | SOpen-market sale Voting Common Stock10b5-1 | -9,645 | $28.12 | $271k | 375,480 | May 6, 2026 |
| May 5, 2026 | Erin Pennock Foff Chief Medical Officer | SOpen-market sale Voting Common Stock10b5-1 | -931 | $29.00 | $27k | 374,549 | May 6, 2026 |
| May 6, 2026 | Erin Pennock Foff Chief Medical Officer | SOpen-market sale Voting Common Stock10b5-1 | -8,152 | $28.04 | $229k | 366,397 | May 6, 2026 |
| May 6, 2026 | Erin Pennock Foff Chief Medical Officer | SOpen-market sale Voting Common Stock10b5-1 | -15,900 | $29.13 | $463k | 350,497 | May 6, 2026 |
| Apr 27, 2026 | Jonathan Gillis CAAO and PAO | SOpen-market sale Voting Common Stock10b5-1 | -7,914 | $28.94 | $229k | 243,140 | Apr 29, 2026 |
| Apr 27, 2026 | Jonathan Gillis CAAO and PAO | SOpen-market sale Voting Common Stock10b5-1 | -29,623 | $29.60 | $877k | 213,517 | Apr 29, 2026 |
| Apr 27, 2026 | Jonathan Gillis CAAO and PAO | SOpen-market sale Voting Common Stock10b5-1 | -14,363 | $30.46 | $437k | 199,154 | Apr 29, 2026 |
| Apr 28, 2026 | Jonathan Gillis CAAO and PAO | SOpen-market sale Voting Common Stock10b5-1 | -17,235 | $30.33 | $523k | 181,919 | Apr 29, 2026 |
| Apr 28, 2026 | Jonathan Gillis CAAO and PAO | SOpen-market sale Voting Common Stock10b5-1 | -700 | $30.83 | $22k | 181,219 | Apr 29, 2026 |
| Apr 15, 2026 | Erin Pennock Foff Chief Medical Officer | SOpen-market sale Voting Common Stock | -2,044 | $26.84 | $55k | 401,946 | Apr 17, 2026 |
| Apr 15, 2026 | Jonathan Gillis CAAO and PAO | SOpen-market sale Voting Common Stock | -3,590 | $26.61 | $96k | 251,054 | Apr 17, 2026 |
| Apr 15, 2026 | Kristopher Hanson General Counsel | SOpen-market sale Voting Common Stock | -1,529 | $26.80 | $41k | 190,463 | Apr 17, 2026 |
| Apr 16, 2026 | Kristopher Hanson General Counsel | SOpen-market sale Voting Common Stock | -73 | $27.01 | $1,972 | 190,390 | Apr 17, 2026 |
| Apr 16, 2026 | Erin Pennock Foff Chief Medical Officer | SOpen-market sale Voting Common Stock | -288 | $27.01 | $7,779 | 401,658 | Apr 17, 2026 |
| Apr 16, 2026 | Erin Pennock Foff Chief Medical Officer | SOpen-market sale Voting Common Stock | -881 | $27.49 | $24k | 400,777 | Apr 17, 2026 |
| Apr 16, 2026 | Kristopher Hanson General Counsel | SOpen-market sale Voting Common Stock | -225 | $27.49 | $6,185 | 190,165 | Apr 17, 2026 |
| Feb 20, 2026 | Robert C. Malenka director | SOpen-market sale Voting Common Stock | -2,195 | $18.03 | $40k | 337,059 | Feb 24, 2026 |
| Feb 23, 2026 | Robert C. Malenka director | SOpen-market sale Voting Common Stock | -10,788 | $18.39 | $198k | 326,271 | Feb 24, 2026 |
| Feb 23, 2026 | Robert C. Malenka director | SOpen-market sale Voting Common Stock | -476 | $19.06 | $9,073 | 325,795 | Feb 24, 2026 |
| Feb 24, 2026 | Robert C. Malenka director | SOpen-market sale Voting Common Stock | -736 | $18.15 | $13k | 325,059 | Feb 24, 2026 |
| Feb 18, 2026 | George Pavlov director | POpen-market purchase Voting Common Stock | +10,658 | $17.48 | $186k | 10,658 | Feb 20, 2026 |
| Feb 19, 2026 | George Pavlov director | POpen-market purchase Voting Common Stock | +4,422 | $17.57 | $78k | 15,080 | Feb 20, 2026 |
| Feb 20, 2026 | George Pavlov director | POpen-market purchase Voting Common Stock | +9,920 | $17.86 | $177k | 25,000 | Feb 20, 2026 |
| Feb 13, 2026 | Robert C. Malenka director | SOpen-market sale Voting Common Stock | -12,116 | $18.21 | $221k | 339,254 | Feb 18, 2026 |
| Feb 10, 2026 | Timothy John Garnett director | POpen-market purchase Voting Common Stockindirect: See footnote | +14,124 | $17.89 | $253k | 14,124 | Feb 12, 2026 |
| Feb 10, 2026 | Robert C. Malenka director | SOpen-market sale Voting Common Stock | -6,622 | $18.12 | $120k | 351,611 | Feb 12, 2026 |
| Feb 11, 2026 | Robert C. Malenka director | SOpen-market sale Voting Common Stock | -241 | $18.00 | $4,338 | 351,370 | Feb 12, 2026 |
| Feb 5, 2026 | Jonathan Gillis CAAO and PAO | AGrant or award Voting Common Stock | +6,020 | $0.00 | $0 | 254,523 | Feb 9, 2026 |
| Feb 5, 2026 | Erin Pennock Foff Chief Medical Officer | AGrant or award Voting Common Stock | +13,360 | $0.00 | $0 | 403,835 | Feb 9, 2026 |
Insiders
Everyone who has filed a Form 4 here.
- Martin Bablerdirector, ceo, president, chair, officer
- Catalyst4, Inc.owner
- Troy Coxdirector
- Erin Pennock FoffChief Medical Officer
- Jonathan GillisCAAO and PAO
- Timothy John Garnettdirector
- Kristopher HansonGeneral Counsel
- Robert C. Malenkadirector
- Novo Holdings A/Sowner
- George Pavlovdirector
Questions about MPLT
Answered from the filings on this page, as of the latest one.
Are insiders buying MPLT?
As of Sep 18, 2026, SEC Form 4 filings show 0 open-market buys worth $0 by 0 insiders and 1 open-market sell worth $193k by 1 insider at MapLight Therapeutics, Inc. in the last 90 days, net -$193k. Only purchases (code P) and sales (code S) count; grants, option exercises and tax withholding do not.
Who was the last insider to trade MPLT on the open market?
Kristopher Hanson (General Counsel) sold $193k of MPLT on Sep 16, 2026 and filed the Form 4 on Sep 18, 2026. InsiderTell scored 12 (weak), under a 10b5-1 plan.
How many insiders file Form 4 at MapLight Therapeutics, Inc.?
10 people have filed a Form 4 at MapLight Therapeutics, Inc., among them Martin Babler (director, CEO, president and chair), Catalyst4, Inc. (10% owner), Troy Cox (director). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.